Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2-3/2015

01-06-2015

Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis

Authors: Guanghua Rong, Hong Wang, Christopher L. Bowlus, Chunping Wang, Yinying Lu, Zhen Zeng, Jianhui Qu, Min Lou, Yan Chen, Linjing An, Yongping Yang, M. Eric Gershwin

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2015

Login to get access

Abstract

The incidence, risk factors, and clinical features of hepatocellular carcinoma (HCC) in primary biliary cirrhosis (PBC) have been a long-standing subject of interest. We took advantage of a large cohort of 1865 well-defined Chinese patients with PBC for whom follow-up was conducted for up to 20 years to study the incidence of HCC. Our goal was to address the incidence and prevalence of HCC in PBC and the risk factors, including hepatitis B virus (HBV) infection, and finally to compare the tumor characteristics of PBC-related HCC, including size, location, mortality, and long-term outcomes, to that of HBV-related HCC. In this cohort, HCC occurred in 70 of 1865 PBC patients with a prevalence of 3.75 % and an incidence of 0.66 cases per 100 patient-years. The 5- and 10-year cumulative incidences were 2.6 % (95 % confidence interval (CI) 1.8–3.4) and 8.9 % (95 % CI 5.5–12.3), respectively. Age >54 years (odds ratio [OR] = 5.5, 95 % CI 3.0–10.1, p = 0.001), male sex (OR = 2.2, 95 % CI 1.2–4.0, p = 0.001), co-existence of diabetes mellitus (DM) (OR = 3.1, 95 % CI 1.6–6.2, p = 0.002), and previous HBV infection (OR = 6.6, 95 % CI 3.7–11.9, p = 0.001) were independently associated with the development of HCC. The tumor size, number, location, and 5-year survival were not significantly different in PBC-related HCC compared to HBV-related HCC. Alpha-fetoprotein was elevated in only 20 % of the cases with PBC-related HCC. Although HCC was uncommon, occurring in fewer than 5 % of patients, the risk is significantly increased by age, sex, DM, and past HBV infection.
Literature
1.
go back to reference Huang W, Kachapati K, Adams D et al (2014) Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun 50:123–134CrossRefPubMed Huang W, Kachapati K, Adams D et al (2014) Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun 50:123–134CrossRefPubMed
2.
go back to reference Liaskou E, Hirschfield GM, Gershwin ME (2014) Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol 36:553–568CrossRefPubMed Liaskou E, Hirschfield GM, Gershwin ME (2014) Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol 36:553–568CrossRefPubMed
3.
go back to reference Wang L, Sun Y, Zhang Z et al (2015) CXCR5 CD4 T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 61:627–638 Wang L, Sun Y, Zhang Z et al (2015) CXCR5 CD4 T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 61:627–638
4.
go back to reference Yang CY, Ma X, Tsuneyama K et al (2014) IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 59:1944–1953CrossRefPubMed Yang CY, Ma X, Tsuneyama K et al (2014) IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 59:1944–1953CrossRefPubMed
5.
go back to reference Yao Y, Yang W, Yang YQ et al (2014) Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha(-/-) mice. J Autoimmun 51:99–108CrossRefPubMed Yao Y, Yang W, Yang YQ et al (2014) Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha(-/-) mice. J Autoimmun 51:99–108CrossRefPubMed
6.
go back to reference Zhang J, Zhang W, Leung PS et al (2014) Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology 60:1708–1716CrossRefPubMed Zhang J, Zhang W, Leung PS et al (2014) Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology 60:1708–1716CrossRefPubMed
7.
go back to reference Lleo A, Zhang W, McDonald WH et al (2014) Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 60:1314–1323CrossRefPubMed Lleo A, Zhang W, McDonald WH et al (2014) Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 60:1314–1323CrossRefPubMed
8.
go back to reference Selmi C, Bowlus CL, Gershwin ME, Coppel RL (2011) Primary biliary cirrhosis. Lancet 377:1600–1609CrossRefPubMed Selmi C, Bowlus CL, Gershwin ME, Coppel RL (2011) Primary biliary cirrhosis. Lancet 377:1600–1609CrossRefPubMed
9.
go back to reference Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50CrossRefPubMed Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50CrossRefPubMed
10.
go back to reference Trivedi PJ, Lammers WJ, van Buuren HR et al (2015) Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. doi:10.1136/gutjnl-2014-308351 Trivedi PJ, Lammers WJ, van Buuren HR et al (2015) Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. doi:10.​1136/​gutjnl-2014-308351
11.
go back to reference Cavazza A, Caballería L, Floreani A et al (2009) Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 50:1162–1168CrossRefPubMed Cavazza A, Caballería L, Floreani A et al (2009) Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 50:1162–1168CrossRefPubMed
12.
go back to reference Harada K, Hirohara J, Ueno Y et al (2013) Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 57:1942–1949CrossRefPubMed Harada K, Hirohara J, Ueno Y et al (2013) Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 57:1942–1949CrossRefPubMed
13.
go back to reference Teuber G, Schaefer A, Berger A et al (2010) Previous hepatitis B virus (HBV) infection is a strong risk factor for the severity of inflammatory activity and the extent of fibrosis in patients with chronic hepatitis C. Hepatology 52:1236A Teuber G, Schaefer A, Berger A et al (2010) Previous hepatitis B virus (HBV) infection is a strong risk factor for the severity of inflammatory activity and the extent of fibrosis in patients with chronic hepatitis C. Hepatology 52:1236A
14.
go back to reference Tanaka K, Nagao Y, Ide T, Kumashiro R, Sata M (2006) Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study. Int J Mol Med 17:827–832PubMed Tanaka K, Nagao Y, Ide T, Kumashiro R, Sata M (2006) Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study. Int J Mol Med 17:827–832PubMed
15.
go back to reference Ohba K, Kubo S, Tamori A et al (2004) Previous or occult hepatitis B virus infection in hepatitis B surface antigen-negative and anti-hepatitis C-negative patients with hepatocellular carcinoma. Surg Today 34:842–848CrossRefPubMed Ohba K, Kubo S, Tamori A et al (2004) Previous or occult hepatitis B virus infection in hepatitis B surface antigen-negative and anti-hepatitis C-negative patients with hepatocellular carcinoma. Surg Today 34:842–848CrossRefPubMed
16.
go back to reference Marusawa H, Osaki Y, Kimura T et al (1999) High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 45:284–288CrossRefPubMedCentralPubMed Marusawa H, Osaki Y, Kimura T et al (1999) High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 45:284–288CrossRefPubMedCentralPubMed
17.
go back to reference Ikeda K, Marusawa H, Osaki Y et al (2007) Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma. A prospective study. Ann Intern Med 146:649–656CrossRefPubMed Ikeda K, Marusawa H, Osaki Y et al (2007) Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma. A prospective study. Ann Intern Med 146:649–656CrossRefPubMed
18.
go back to reference Ikeda K, Kobayashi M, Someya T et al (2009) Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 16:437–443CrossRefPubMed Ikeda K, Kobayashi M, Someya T et al (2009) Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 16:437–443CrossRefPubMed
19.
go back to reference Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K (2008) Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 43:849–856CrossRefPubMed Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K (2008) Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 43:849–856CrossRefPubMed
20.
go back to reference Lu J, Zhou Y, Lin X et al (2009) General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 4:e8467CrossRefPubMedCentralPubMed Lu J, Zhou Y, Lin X et al (2009) General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 4:e8467CrossRefPubMedCentralPubMed
21.
go back to reference Gao J, Xie L, Yang WS et al (2012) Risk factors of hepatocellular carcinoma—current status and perspectives. Asian Pac J Cancer Prev 13:743–752CrossRefPubMed Gao J, Xie L, Yang WS et al (2012) Risk factors of hepatocellular carcinoma—current status and perspectives. Asian Pac J Cancer Prev 13:743–752CrossRefPubMed
22.
go back to reference Bogdanos DP, Komorowski L (2011) Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 412:502–512CrossRefPubMed Bogdanos DP, Komorowski L (2011) Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 412:502–512CrossRefPubMed
23.
go back to reference Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50:291–308CrossRefPubMed Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50:291–308CrossRefPubMed
24.
25.
go back to reference Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:061–074CrossRef Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:061–074CrossRef
26.
go back to reference Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association (2010) Guidelines for diagnosis and treatment for alcoholic liver diseases. Chin J Clin Hepatol 2:49–53 Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association (2010) Guidelines for diagnosis and treatment for alcoholic liver diseases. Chin J Clin Hepatol 2:49–53
27.
go back to reference Granito A, Yang W-H, Muratori L et al (2009) PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 105:125–131CrossRefPubMed Granito A, Yang W-H, Muratori L et al (2009) PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 105:125–131CrossRefPubMed
28.
go back to reference Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M (2011) Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 50:1–10CrossRefPubMed Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M (2011) Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 50:1–10CrossRefPubMed
29.
go back to reference Findor J, He X-S, Sord J, Terg R, Gershwin ME (2002) Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev 1:220–225CrossRefPubMed Findor J, He X-S, Sord J, Terg R, Gershwin ME (2002) Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev 1:220–225CrossRefPubMed
30.
go back to reference Macaron C, Hanouneh IA, Zein NN (2010) Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 52:2240CrossRef Macaron C, Hanouneh IA, Zein NN (2010) Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 52:2240CrossRef
31.
go back to reference Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1:1357–1360CrossRefPubMed Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1:1357–1360CrossRefPubMed
32.
go back to reference Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J (2001) Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 96:1160–1163PubMed Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J (2001) Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 96:1160–1163PubMed
33.
go back to reference Farinati F, Floreani A, De Maria N, Fagiuoli S, Naccarato R, Chiaramonte M (1994) Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol 21:315–316CrossRefPubMed Farinati F, Floreani A, De Maria N, Fagiuoli S, Naccarato R, Chiaramonte M (1994) Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol 21:315–316CrossRefPubMed
34.
go back to reference Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P (2001) Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 34:194–203CrossRefPubMed Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P (2001) Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 34:194–203CrossRefPubMed
35.
go back to reference Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170CrossRefPubMed Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170CrossRefPubMed
36.
go back to reference Bréchot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127:S56–S61CrossRefPubMed Bréchot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127:S56–S61CrossRefPubMed
37.
go back to reference Lok AS, Sterling RK, Everhart JE et al (2010) Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138:493–502CrossRefPubMedCentralPubMed Lok AS, Sterling RK, Everhart JE et al (2010) Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138:493–502CrossRefPubMedCentralPubMed
38.
go back to reference Trevisani F, D'Intino PE, Morselli-Labate AM et al (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34:570–575CrossRefPubMed Trevisani F, D'Intino PE, Morselli-Labate AM et al (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34:570–575CrossRefPubMed
39.
go back to reference Shibuya A, Tanaka K, Miyakawa H et al (2002) Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35:1172–1178CrossRefPubMed Shibuya A, Tanaka K, Miyakawa H et al (2002) Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35:1172–1178CrossRefPubMed
40.
go back to reference Kuiper EM, Hansen BE, Adang RP et al (2010) Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 22:1495–1502PubMed Kuiper EM, Hansen BE, Adang RP et al (2010) Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 22:1495–1502PubMed
Metadata
Title
Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis
Authors
Guanghua Rong
Hong Wang
Christopher L. Bowlus
Chunping Wang
Yinying Lu
Zhen Zeng
Jianhui Qu
Min Lou
Yan Chen
Linjing An
Yongping Yang
M. Eric Gershwin
Publication date
01-06-2015
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2015
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-015-8483-x

Other articles of this Issue 2-3/2015

Clinical Reviews in Allergy & Immunology 2-3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine